The Lustgarten Foundation is the largest private funder of the world’s preeminent pancreatic cancer researchers.
To date, we have funded more than $250 million in research grants and been a leading force in every major advancement in pancreatic cancer research.
Progress is paramount. We drive bold, innovative research with the singular mission: transforming pancreatic cancer into a curable disease.
Lustgarten Announcements
Our roundtable of experts from across the cancer continuum will discuss what is changing in clinical care and how research is driving these developments.
In 2022, your generosity fueled Lustgarten-funded researchers’ significant progress in pancreatic cancer research. Together, we are advancing research from the laboratory to the clinic faster than ever before, giving renewed hope to patients and their families. We have funded 318 research projects across 81 academic institutions, improving the lives of countless impacted individuals. As Lustgarten […]
The American Cancer Society (ACS) has released its Cancer Facts & Figures 2023, an annual summary of the current scientific information about cancer. The report highlighted progress in the five-year survival rate of pancreatic cancer while the incidence trend continues to increase year over year. The overall risk of cancer is declining, but it remains […]
News From The Field
Netris Pharma – a company focused on receptor biology – has revealed that the first patient has been dosed during a multi-location, proof-of-concept trial.
Researchers have uncovered an unusual way some cancer cells make nutrients they need to grow, a discovery that could hold the key to starving one of America’s deadliest cancers with a drug we already possess.
Transcenta Holding Limited (“Transcenta”) (HKEX: 06628) announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Osemitamab (TST001), its high affinity humanized ADCC-enhanced anti-Claudin18.2 monoclonal antibody, for the treatment of patients with pancreatic cancer.
SUSAN’s story
From Nurse to Patient
When Susan was diagnosed with pancreatic cancer, cutting-edge drugs and a supportive medical team helped her go from patient to survivor. Now she raises funds for continued research through a Lustgarten Foundation Walk for Research.
Read Susan’s Story
